October 29, 2014 | Israeli pharmaceutical company BiondVax, developing the universal flu vaccine, announced that it received approvals from the European Union and Japan’s patent authorities for the companies flu vaccines. The Multimeric Multi-Epitope Polypeptide Influenza Vaccines is a family of patents for vaccination against influenza in humans, vaccines that provide long-lasting protecting against a variety of flu strains. The approved patent in Europe and Japan was approved some time ago by authorities in the US, Hong Kong, Australia, China, Russia and Mexico. BiondVax is a publicly traded company that has created a universal flu vaccine to improve global protection against influenza.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
![](https://nocamels.com/wp-content/uploads/2018/02/INSIGHTEC-350x180.jpg)
Israeli Ultrasound Creator Collaborating On Neuroscience R&D In US
September 05, 2024
![The Weizmann Institute of Science. Photo via the Weizmann Institute of Science](https://nocamels.com/wp-content/uploads/2018/07/weizmann-350x252.jpg)
Weizmann In World’s Top 10 For Biomedical And Overall Research
September 05, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/Depositphotos_75148477_L-350x228.jpg)
Israeli NGO Begins New Mental Health Training In Ukraine
September 04, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/17123254699_79ff768811_ks-350x213.jpg)
Nonprofit Launches Loans For Stricken Northern Israel Businesses
September 04, 2024
Facebook comments